Introduction: The Montreal Cognitive Assessment (MoCA) accurately differentiates mild cognitive impairment (MCI) from mild dementia and normal controls (NC). While the MoCA is validated in multiple clinical settings, few studies compare it with similar tests also designed to detect MCI. We sought to investigate how the shorter Quick Mild Cognitive Impairment (Qmci) screen compares with the MoCA. Methods: Consecutive referrals presenting with cognitive complaints to a teaching hospital geriatric clinic (Fremantle, Western Australia) underwent a comprehensive assessment and were classified as MCI (n = 72) or dementia (n = 109). NC (n = 41) were a sample of convenience. The Qmci and MoCA were scored by trained geriatricians, in random order, blind to the diagnosis. Results: Median Qmci scores for NC, MCI and dementia were 69 (+/À19), 52.5 (+/À12) and 36 (+/ À14), respectively, compared with 27 (+/À5), 22 (+/À4) and 15 (+/À7) for the MoCA. The Qmci more accurately identified cognitive impairment (MCI or dementia), area under the curve (AUC) 0.97, than the MoCA (AUC 0.92), p = 0.04. The Qmci was non-significantly more accurate in distinguishing MCI from controls (AUC 0.91 vs 0.84, respectively = 0.16). Both instruments had similar accuracy for differentiating MCI from dementia (AUC of 0.91 vs 0.88, p = 0.35). At the optimal cut-offs, calculated from receiver operating characteristic curves, the Qmci (≤57) had a sensitivity of 91% and specificity of 93% for cognitive impairment, compared with 87% sensitivity and 80% specificity for the MoCA (≤23). Conclusion: While both instruments are accurate in detecting MCI, the Qmci is shorter and arguably easier to complete, suggesting that it is a useful instrument in an Australian geriatric outpatient population.
Introduction
The prevalence of mild cognitive impairment (MCI) is expected to increase worldwide, as populations age (Plassman et al., 2008) . MCI is a heterogeneous disorder, characterised by subtle cognitive deficits, without loss of function with variable progression to dementia (Dubois et al., 2010; Albert et al., 2011) . There is still scepticism about the use of biomarkers in this way, particularly as single diagnostic tests (Ritchie et al., 2014) . Nevertheless, as prognosis and treatment options for MCI and dementia differ (Cooper et al., 2013; Tricco et al., 2013) , an increasing emphasis is placed on early identification and management (Fiatarone Singh et al., 2014; O'Caoimh et al., 2015) of MCI. Identification in clinical practice is, however, limited by a lack of suitable sensitive and specific instruments. Indeed, criteria for this syndrome are numerous, and not all capture change associated with disease (Matthews et al., 2008) . Access to gold standard assessment, with neuropsychological testing is curtailed by a lack of resources necessitating the use of short cognitive instruments that often double as both short screens and cognitive tests in busy clinics. The most widely used instrument is the mini-mental state examination (Folstein et al., 1975) and its standardised version (SMMSE) (Molloy et al., 1991; Molloy and Standish, 1997) , but these are limited by ceiling effects and low sensitivity to mild dementia and MCI. To overcome these problems, the Montreal Cognitive Assessment (MoCA) was developed. The MoCA has high sensitivity for MCI and is widely translated and validated, in different clinical settings (Nasreddine et al., 2005) . The MoCA takes approximately 10 min to complete, but the utility of its original cut-off score (<26) has been questioned (Luis et al., 2009) . The specificity of the MoCA at this cut-off score is low (McLennan and Stewart, 2011) with studies demonstrating specificities as low as 35% (Luis et al., 2009) . To adjust for this, lower cut-off scores for MCI (McLennan and Stewart, 2011; Larner, 2012; Freitas et al., 2013) are proposed. However, uncertainty remains as to which cut-off is most appropriate and in which setting.
The Quick Mild Cognitive Impairment (Qmci) screen is a new, shorter cognitive screen with high sensitivity and specificity for MCI (O'Caoimh et al., 2016) . Derived from an earlier version, the AB cognitive screen 135 (Molloy and Lewis, 2005; Standish et al., 2007) , it was designed to improve sensitivity and specificity, yet retain a short administration time. The Qmci is validated in Canada against the SMMSE and AB cognitive screen 135 (O'Caoimh et al., 2016) , in Dutch against the SMMSE (Bunt et al., 2015) and in Ireland against the six-item cognitive impairment test (O'Caoimh and Molloy, 2014a ), but has not otherwise been externally validated. Given that few studies have compared short cognitive instruments designed specifically to identify MCI, we externally validated the Qmci in an Australian sample by comparing its accuracy to the MoCA. Investigating the performance of short cognitive screening instruments is important, as there is much heterogeneity between study populations with psychometric properties including the accuracy, cut-off points selected and the positive and negative predictive value of instruments varying between studies, particularly where sample sizes differ (Bartlett et al., 2012) . Given this, we chose to validate the Qmci in a geriatric clinic, a setting in which it is yet to be validated and one that is rarely considered for the validation of short cognitive screening instruments despite their frequent use in this setting.
Methods

Data collection
Consecutive referrals of patients with cognitive complaints to a geriatric outpatient clinic at Fremantle Hospital and Health Service, Western Australia, were invited to participate and underwent a comprehensive assessment between December 2013 and June 2015. This was not a specialised memory clinic, but referrals of patients with cognitive symptoms sent to the department were cohorted together. Controls were a sample of convenience. The Qmci and MoCA were administered in clinic, in random order, by trained geriatricians, blind to the final diagnosis. This project was part of a quality improvement project to determine which cognitive assessment tool is optimal for use in a hospital-based geriatric medicine clinic and was approved by the director of Safety, Quality and Risk and the director of Clinical Services at Fremantle Hospital and Health Service as a quality assurance project. This allowed consecutive patients presenting with cognitive symptoms to be included without the requirement for written consent, although participants were informed that additional cognitive testing was being conducted as part of the project.
Multi-disciplinary team (MDT) assessment in those staged with a score of 0.5 on the CDR. Older caregivers attending with patients (n = 2) and older patients attending this general geriatric clinic (n = 39), without memory loss, were invited to participate as normal controls (n = 41). Controls were asked regarding memory loss and underwent a similar MDT assessment as patients. All participants resided in their own homes, and none lived in residential facilities. Participants were excluded if they were aged <45 years, if they presented with depressive (active) symptoms, if they presented to clinic with subjective memory complaints and were found to have normal cognition or if they were not fluent English speakers. Depression was excluded clinically, supported by the Geriatric Depression Scale short from (Yesavage et al., 1982) using a cut-off score of ≥7, targeting high specificity (Marc et al., 2008) .
Outcomes
The Qmci has six subtests (orientation, five-word registration, a clock drawing test, five-word recall, verbal fluency and logical memory, and a test of immediate verbal recall of a short story) and is scored out of 100 points (test available as an online supplement at http://ageing.oxfordjournals.org/content/early/2012/ 05/18/ageing.afs059/suppl/DC1). The logical memory subtest contributes most to the sensitivity and specificity of the instrument (O'Caoimh et al., 2013) . Median administration time is 4.2 min. The Qmci correlates with the CDR, the standardised Alzheimer's Disease Assessment Scale (ADAS)-cog and the Lawton-Brody activities of daily living scale (O'Caoimh et al., 2014b) . The optimal cut-off for the Qmci, for cognitive impairment (MCI or dementia) in a sample of patients attending outpatients in Canada, is ≤62 (O'Caoimh et al., 2014c). The MoCA has seven subtests covering five cognitive domains such as memory, language, visuospatial, attention and cognitive control and is scored out of 30 points (Nasreddine et al., 2005) .
Analysis
Data were analysed using SPSS version 22.0 (SPSS Inc., Chicago, Illinois, USA). Normality was tested using the Shapiro-Wilk test and found that the majority of data were non-parametric. The Mann-Whitney U test was used to compare non-parametric variables. Where more than one group was compared, data were analysed using the Kruskal-Wallis test. The chi-squared test compared frequencies. Accuracy was determined from the area under the curve (AUC) using receiver operating characteristics (ROC) curves. AUC results were classed as excellent if between 1-0.9, good between 0.9-0.8, fair between 0.8-0.7, poor between 0.7-0.6 and failed for those between 0.6-0.5 (Metz, 1978) . Sensitivity, specificity, positive predictive values and negative predictive values were calculated for a range of cut-off scores. Optimal cut-off scores were calculated from the ROC curves and were defined as those that maximised the AUC value. Binary logistic regression was used to control ROC curves for the effects of age and education.
Results
In all, 230 participants were assessed. Of these, eight were excluded: five with subjective memory complaints and normal cognition, one with active depression and two with an uncertain diagnosis. The characteristics of the 222 included are presented in Table 1 . The median age of the sample was 76 years, interquartile range ± 13 years. In all, 115 (52%) were female. No significant differences were found in the gender composition between MCI, dementia and control groups (p = 0.06). There was a high prevalence of cognitive impairment (82%). Of those included, 72 had MCI, 109 had dementia and 41 were normal controls. Subjects with MCI (p < 0.01) and dementia (p < 0.001) were significantly older than controls. Patients with dementia had significantly fewer years of education than control (p = 0.03), but no significant difference was found between MCI and control groups (p = 0.75). The median Qmci score for MCI was 52.5 ± 12 compared with 69 ± 9 for controls (p < 0.001). The median MoCA scores for MCI and normal were 22 ± 3.75 and 27 ± 5, respectively (p < 0.001).
Figure 1 presents ROC curves comparing the ability of the Qmci and MoCA to distinguish controls from MCI and dementia. The Qmci and MoCA both had good-to-excellent accuracy in separating cognitive impairment (either MCI or dementia), from normal controls. The Qmci had a similar AUC in differentiating MCI from normal controls (AUC of 0.91) compared with the MoCA (AUC of 0.84), z = À1.40, p = 0.16. Likewise, there was no significant difference between either instruments accuracy to differentiate MCI from dementia: AUC of 0.91 for the Qmci compared with 0.88 for the MoCA, z = À1.02, p = 0.31. The Qmci and MoCA both had excellent accuracy on identifying cognitive impairment (either MCI or dementia), AUC of 0.97 vs 0.92, respectively, with Qmci having significantly better accuracy than MoCA, z = À2.01, p = 0.04. After correcting the ROC curve analysis for the effects of age and education, the Qmci was still, albeit borderline, statistically significantly more accurate at differentiating cognitive impairment from normal controls (AUC of 0.97; 95% confidence interval: 0.95-0.99) compared with the MoCA (AUC of 0.94; 95% confidence interval: 0.90-0.97), z = 1.67, p = 0.048 (one-tailed).
Based upon sensitivity and specificity analysis, calculated from ROC curves, the optimal Qmci cut-off for cognitive impairment was ≤57. At this cut-off, the Qmci had a sensitivity of 91% and specificity of 93%. The optimal MoCA cut-off in this sample was ≤23 yielding a sensitivity of 87% and specificity of 80%. Optimal cut-off points for MCI were ≤60 for the Qmci and ≤23 for the MoCA. Lower cut-offs were found for dementia, ≤50 and ≤22 for the Qmci and MoCA, respectively. The sensitivity and specificity of both instruments, at these cut points, are presented in Tables 2 and in S3 and S4. 
Conclusion
This study presents the results of the first external validation of the Qmci against the MoCA in a sample of older adults presenting to a geriatric outpatient clinic in Western Australia. The results show both instruments are accurate in differentiating MCI from dementia and controls. While the Qmci had a larger AUC in differentiating MCI from NC, this did not reach statistical significance. The Qmci was, however, statistically significantly better able to distinguish patients with cognitive impairment (MCI or dementia) from controls (p = 0.04). The results found that the optimal Qmci cut-off in distinguishing normal controls from cognitive impairment is ≤50 for the Qmci and ≤22 for the MOCA. This is at odds with the original MoCA data that found that a score ≤26 indicates cognitive impairment (Nasreddine et al., 2005) (Narazaki et al., 2013) . These data show features suggestive of a typical rising age distribution from normal to MCI to dementia in keeping with age as a major risk factor for cognitive decline, albeit this compromised by the highly selected normal control group. However, the distribution of scores across the three groups on the Qmci is consistent with previous studies using the Qmci, which recruited normal, asymptomatic volunteers (O'Caoimh et al., 2012) . The optimal cut point for distinguishing MCI from normal is ≤60 for the Qmci, which is also in accordance with previous studies, although the optimal cutoff for cognitive impairment was slightly lower (≤57) (O'Caoimh and Molloy, 2014a; O'Caoimh et al., 2016) . The optimal cut point for the MoCA in this respect is ≤23, which is similar to that reported in a recent paper by Freitas et al. (2013) . While the Qmci had a larger AUC than the MoCA in differentiating patients with MCI from controls, these differences did not reach statistical significance. Although both tests had high scores for sensitivity, specificity, positive predictive values and negative predictive values, the Qmci had a higher sensitivity and specificity than the MoCA in differentiating normal from MCI at their optimal cut-offs (selected using the maximal accuracy approach). This suggests that the Qmci may be the better test to use in a geriatric clinic setting where both high sensitivity and specificity are desirable.
There are several limitations in this study. The sample size was small, particularly with respect to the number of people with normal cognition, and while representative of a geriatric clinic could potentially under-power the study to show superiority of one instrument over the other in a general practice setting. The controls were obtained by testing patients who presented to the clinic with non-cognitive problems Table 2 Sensitivity, specificity, PPV and NPV, with 95% CI, for different Quick Mild Cognitive Impairment screen and MoCA cut-off scores for cognitive impairment (mild cognitive impairment and dementia), without adjustment for age or education, compared with normal controls Cut-off score Sensitivity (95% CI)
PPV, positive predictive value; NPV, negative predictive value; CI, confidence intervals; MoCA, Montreal Cognitive Assessment.
and also from family members of patients. Future studies should include patients presenting with subjective memory complaints. However, the numbers of these patients attending a general geriatric clinic are expected to be small. We excluded obvious clinical states, and participants were reviewed by MDT assessment, but we cannot be certain that these controls were truly normal. Further, there is over representation in the sample by the dementia group. However, it is arguable that the pre-test probability of finding cognitive impairment is so high in these symptomatic older adults attending geriatric outpatients that this equates to a case-finding exercise to rule in the condition. In this setting that normal controls were younger and less in number does not detract from the comparison of the accuracy of the instruments. Indeed, adjusting for age and education did not affect the ROC curve analysis.
Another limitation is that we cannot assume that the population is representative of all geriatric medicine clinics in Australia, particularly as patients with memory complaints are cohorted in our geriatric department. However, there is a sufficient uniformity of geriatric medicine practice in Australia to allow one to consider this patient population to be not inconsistent with those seen in other clinics Australia wide. Prevalence data for cognitive disorders are not available for Australian states, but we estimate that there are approximately 3000 individuals with dementia living in the catchment area of our hospital (Australian Institute of Health and Welfare, 2012) . The size of our sample is reflective of the community prevalence of cognitive disorders. Furthermore, external validation in other samples, particularly community samples, for example, in general practice with a lower prevalence or dedicated memory clinics with a higher prevalence of cognitive impairment, and using other study approaches including prospective designs are required to evaluate the psychometric properties including appropriate cut-off scores in these settings.
Another limitation is that formal neuropsychological testing was not performed on all subjects but the use of the CDR provided a robust basis for the syndromal diagnoses of MCI and dementia. Many patients had a disease diagnosis based on imaging findings and MDT. The commonest diagnosis was Alzheimer's disease. The NINCDS criteria were used for the latter and Diagnostic and Statistical Manual of Mental Disorders IV used for identifying dementia supported by the CDR.
Finally, the method of producing the optimal cutoff scores used in this study (the maximal accuracy approach) is not a gold standard and assumes that false positives and negatives are equally desirable. It also depends on the prevalence of cognitive impairment, which in this case was high, rendering the cut-offs appropriate for use in a memory clinic, where prevalence is expected to be high, but potentially inappropriate for screening in general practice (Bartlett et al., 2012; Larner, 2015) .
In summary, this study presents the first external validation of a new short cognitive screening instrument designed to separate MCI from mild dementia and normal cognition, the Qmci screen. In this sample, of those attending a geriatric medicine clinic at Fremantle Hospital, both the MoCA and Qmci were accurate in identifying MCI and differentiating it from normal controls and dementia although the Qmci had a higher sensitivity and specificity at their optimal cut-off. These results also reaffirm that the original cut-off for the MoCA, ≤26, is inappropriate in older adults and suggests that if a cut-off is to be considered, then ≤23 for MCI and ≤22 for dementia may be optimal. Given the shorter administration time and excellent accuracy shown in this study, we suggest that the Qmci is at worst non-inferior to the MoCA in distinguishing between normal cognition, MCI and dementia and may be a better choice for a short cognitive instrument to use in a geriatric outpatients clinic.
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Key points
• Few studies are available comparing short screens specifically designed to identify mild cognitive impairment (MCI).
• This study provides the first external validation of the Quick Mild Cognitive Impairment screen against the well-established Montreal Cognitive Assessment in an older sample of patients attending a geriatric clinic in Western Australia.
• After correcting for the effects of age and education, the Quick Mild Cognitive Impairment was statistically significantly more accurate than the Montreal Cognitive Assessment at differentiating cognitive impairment (MCI and dementia) from normal controls. There was no difference in distinguishing MCI from normal controls.
• Given the small sample size and select population, further study is required to confirm these findings. 
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